443 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Kesler Norman & Wride LLC

Kesler Norman & Wride LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 443 shares of the biopharmaceutical company's stock, valued at approximately $316,000.

Other institutional investors have also bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $151,000. Paloma Partners Management Co grew its holdings in shares of Regeneron Pharmaceuticals by 1,789.2% during the 3rd quarter. Paloma Partners Management Co now owns 625 shares of the biopharmaceutical company's stock worth $657,000 after purchasing an additional 662 shares during the period. Bamco Inc. NY acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $4,731,000. Benjamin Edwards Inc. raised its holdings in Regeneron Pharmaceuticals by 12,448.0% in the 3rd quarter. Benjamin Edwards Inc. now owns 3,137 shares of the biopharmaceutical company's stock valued at $3,298,000 after buying an additional 3,112 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Regeneron Pharmaceuticals by 76.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 23,591 shares of the biopharmaceutical company's stock worth $24,800,000 after buying an additional 10,213 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on REGN shares. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Finally, Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $4.56 on Monday, hitting $568.89. The company had a trading volume of 798,378 shares, compared to its average volume of 688,563. The business has a 50 day moving average of $676.70 and a 200 day moving average of $776.59. Regeneron Pharmaceuticals, Inc. has a 52-week low of $536.30 and a 52-week high of $1,211.20. The company has a market cap of $62.19 billion, a PE ratio of 14.83, a PEG ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business earned $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.